The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Diversity, Equity and Inclusivity in Parkinson's research, 2021Study of Cognitive Differences in a South Asian Population with Parkinson’s Disease
Study Rationale: Research on Parkinson’s disease (PD) has focused mainly on White, affluent populations. Little is known about PD in people of color. East London is one of the most diverse parts of...
-
Research Grant, 2013Validation of the Movement Disorders Society Criteria for Mild Cognitive Impairment in Parkinson’s Disease
Objective/Rationale:
Dementia in Parkinson’s disease (PD) is a serious health issue and a major concern for many PD patients. Mild cognitive impairment (MCI) is considered a transitional... -
Improved Biomarkers and Clinical Outcome Measures, 2015Validation of a Performance-based Assessment of Functional Ability Related to Cognition in Parkinson’s Disease
Study Rationale:
There is a pressing need for new treatments to address cognitive impairment in Parkinson’s disease, yet there is no consensus on how to best evaluate their... -
Repositioning Drugs for PD, 2011Droxidopa Treatment for Cognitive Impairment in Parkinson's Disease
Objective/Rationale:
Memory, concentration, and other cognitive operations are sometimes impaired in Parkinson's disease (PD), but available treatment options are very limited. This project will test... -
Rapid Response Innovation Awards, 2014Inhibition of Striatal-Enriched Phosphatase (STEP) to Improve Parkinson-Related Cognitive Dysfunction
Study Rationale:
As the enzyme striatal-enriched phosphatase (STEP) may be abnormally elevated in aged parkinsonian pre-clinical models with cognitive deficits, the possibility... -
Research Grant, 2020Parkinson’s Disease with Mild Cognitive Impairment Treated with a Nicotinic Agonist Drug
Study Rationale:
Parkinson’s disease with mild cognitive impairment (PD-MCI) is common, has important clinical consequences, and there is currently no treatment available. The underlying pathology of...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.